These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. An open, noncomparative study of amoxapine in borderline disorders. Jensen HV; Andersen J Acta Psychiatr Scand; 1989 Jan; 79(1):89-93. PubMed ID: 2648768 [TBL] [Abstract][Full Text] [Related]
5. The validity of DSM-III borderline personality disorder. A phenomenologic, family history, treatment response, and long-term follow-up study. Pope HG; Jonas JM; Hudson JI; Cohen BM; Gunderson JG Arch Gen Psychiatry; 1983 Jan; 40(1):23-30. PubMed ID: 6849616 [TBL] [Abstract][Full Text] [Related]
6. DSM-III and DSM-III-R schizotypal symptoms in borderline personality disorder. Silk KR; Westen D; Lohr NE; Benjamin J; Gold L Compr Psychiatry; 1990; 31(2):103-10. PubMed ID: 2311377 [TBL] [Abstract][Full Text] [Related]
7. Pharmacotherapy of the borderline patient: a critical review and clinical guidelines. Kutcher SP; Blackwood DH Can J Psychiatry; 1989 May; 34(4):347-53. PubMed ID: 2567621 [TBL] [Abstract][Full Text] [Related]
8. Psychopharmacologic management of patients with borderline personality disorder. Links PS; Steiner M Can J Psychiatry; 1988 Jun; 33(5):355-9. PubMed ID: 3044565 [TBL] [Abstract][Full Text] [Related]
9. Discriminant efficiency of antisocial and borderline personality disorder criteria in Hispanic men with substance use disorders. Becker DF; Grilo CM; Anez LM; Paris M; McGlashan TH Compr Psychiatry; 2005; 46(2):140-6. PubMed ID: 15723032 [TBL] [Abstract][Full Text] [Related]
10. Fluoxetine treatment of impulsive aggression in DSM-III-R personality disorder patients. Coccaro EF; Astill JL; Herbert JL; Schut AG J Clin Psychopharmacol; 1990 Oct; 10(5):373-5. PubMed ID: 2258454 [No Abstract] [Full Text] [Related]
11. Identifying the unique and common characteristics among the DSM-IV antisocial, borderline, and narcissistic personality disorders. Holdwick DJ; Hilsenroth MJ; Castlebury FD; Blais MA Compr Psychiatry; 1998; 39(5):277-86. PubMed ID: 9777280 [TBL] [Abstract][Full Text] [Related]
12. [Psychopharmacotherapy in adolescents with borderline personality disorder in inpatient and outpatient psychiatric treatment]. Wöckel L; Goth K; Matic N; Zepf FD; Holtmann M; Poustka F Z Kinder Jugendpsychiatr Psychother; 2010 Jan; 38(1):37-49. PubMed ID: 20047175 [TBL] [Abstract][Full Text] [Related]
13. Borderline personality disorder: study in adolescence. James A; Berelowitz M; Vereker M Eur Child Adolesc Psychiatry; 1996 Apr; 5(1):11-7. PubMed ID: 9117533 [TBL] [Abstract][Full Text] [Related]
14. Psychopharmacologic approaches to the borderline patient. Zisook S; Ricketts JE Hillside J Clin Psychiatry; 1988; 10(1):55-70. PubMed ID: 2900799 [TBL] [Abstract][Full Text] [Related]
15. The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder. Zanarini MC; Frankenburg FR; Hennen J; Silk KR Am J Psychiatry; 2003 Feb; 160(2):274-83. PubMed ID: 12562573 [TBL] [Abstract][Full Text] [Related]
16. Pro re nata (as needed) psychotropic medication use in patients with borderline personality disorder and subjects with other personality disorders over 14 years of prospective follow-up. Martinho E; Fitzmaurice GM; Frankenburg FR; Zanarini MC J Clin Psychopharmacol; 2014 Aug; 34(4):499-503. PubMed ID: 24875066 [TBL] [Abstract][Full Text] [Related]
17. Clinical study of the relation of borderline personality disorder to Briquet's syndrome (hysteria), somatization disorder, antisocial personality disorder, and substance abuse disorders. Hudziak JJ; Boffeli TJ; Kreisman JJ; Battaglia MM; Stanger C; Guze SB Am J Psychiatry; 1996 Dec; 153(12):1598-606. PubMed ID: 8942457 [TBL] [Abstract][Full Text] [Related]
18. Are there borderlines in Britain? A cross-validation of US findings. Kroll J; Carey K; Sines L; Roth M Arch Gen Psychiatry; 1982 Jan; 39(1):60-3. PubMed ID: 7055409 [TBL] [Abstract][Full Text] [Related]